Answers are grounded in this paper and cite their sources.
Compares safety of thrombolysis in oncological and non-oncological patients, suggesting no significant bleeding difference.
• In oncological patients PE represents the second cause of mortality after death due to the cancer itself. • The effectiveness and safety of catheter-directed therapies for acute PE has been rarely investigated in oncological patients. • In this study, oncological patients affected by intermediate-high risk PE and treated with ultrasound-facilitated catheter-directed thrombolysis, were compared to non oncological patients in terms of bleeding complications (defined as BARC > 3a) and need for transfusions. • When comparing bleeding complications no significant differences were found between patients with active cancer and those without.
No takes yet. Share an insight, caveat, or question.
Colombo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: